[1] 连利娟.林巧稚妇科肿瘤学[M].4版.北京:人民卫生出版社,2006:580. [2] Bell J,Brady MF,Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study[J].Gynecol Oncol,2006,102(3):432-439. [3] Bertelsen K,Jakobsen A,Str yer J,et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA) [J].Gynecol Oncol,1993,49(1):30-36. [4] 黄永文,李玉洁,李孟达.Ⅱ~Ⅳ期上皮性卵巢癌术后化疗方案选择和疗程优化的探讨[J].癌症,2005,24(8):994-997. [5] 黄啸,蔡树模,汤洁,等.综合性治疗复发性卵巢癌上皮性癌的疗效及预后分析[J].中华妇产科杂志,2004,39:602-605. [6] Iwase H, Takada T, Iitsuka C, et al.Clinical features of long-term survivors of recurrent epithelial ovarian cancer[J].Int J Clin Oncol,2014,Mar 26. [Epub ahead of print] [7] 周慧梅,黄慧芳,潘凌亚,等.血清CA125值的变化对判断上皮性卵巢癌疗效及预后的临床研究[J].中国实用妇科与产科杂志,2008,24(3):204-206. [8] Van Altena AM,Kolwijck E,Spanjer MJ,et al.CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study[J].Gynecol Oncol,2010,119(2):265-269. |